Toggle Nav
Close
  • Menu
  • Setting

Tirapazamine

Catalog No.
B3399
Anticancer drug
Grouped product items
SizePriceStock Qty
10mM (in 1mL DMSO)
$72.00
In stock
50mg
$66.00
In stock
200mg
$195.00
In stock
For scientific research use only and should not be used for diagnostic or medical purposes.

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background

Tirapazamine (CAS 27314-97-2), also known as SR259075, Win59075, or SR4233, is an investigational anticancer agent selectively activated under hypoxic conditions characteristic of solid tumors. The compound is bioreduced in hypoxic tumor microenvironments to cytotoxic free radicals, leading to cellular damage. Tirapazamine downregulates hypoxia-inducible factor-1α (HIF-1α), thereby influencing pathways associated with tumor adaptive mechanisms to hypoxia. Combined treatment with tirapazamine and topoisomerase I inhibitors (such as SN-38, the active metabolite of irinotecan) enhances apoptosis via mitochondria-mediated caspase activation and weakened DNA repair signaling. Preclinical investigations, including hepatocellular carcinoma xenografts, confirm this enhanced tumor suppression. Clinical trials evaluating tirapazamine's anticancer efficacy are ongoing.

Product Citation

Chemical Properties

Physical AppearanceA solid
StorageStore at -20°C
M.Wt178.15
Cas No.27314-97-2
FormulaC7H6N4O2
Solubilityinsoluble in H2O; insoluble in EtOH; ≥8.9 mg/mL in DMSO
Chemical Name4-hydroxy-1-oxido-1,2,4-benzotriazin-1-ium-3-imine
SDFDownload SDF
Canonical SMILESC1=CC=C2C(=C1)N(C(=N)N=[N+]2[O-])O
Shipping ConditionSmall Molecules with Blue Ice, Modified Nucleotides with Dry Ice.
General tips We do not recommend long-term storage for the solution, please use it up soon.

Protocol

Cell experiment:[1]

Cell lines

Human liver cancer Bel-7402 cells

Reaction Conditions

0 ~ 10 μM tirapazamine

Applications

Tirapazamine dose-dependently inhibited the transcriptional activity (0 ~ 10 μM; 6 h) and the protein level (0 ~ 10 μM; 12 h) of HIF-1α under hypoxia. Moreover, tirapazamine (0 ~ 5 μM; 24 h) enhanced the cytotoxicity elicited by topoisomerase I inhibitors (i.e. SN-38, TPT, HCPT and MONCPT) under hypoxic conditions.

Animal experiment:[1]

Animal models

5- to 6-week-old BALB/c male athymic mice xenografted with Bel-7402 cells

Dosage form

25 mg/kg

Administered by intraperitoneal injection every 2 days for 27 days

Applications

The combination of tirapazamine and irinotecan caused marked tumor growth inhibition that was significantly greater than that caused by tirapazamine or irinotecan treatment alone. Furthermore, compared with the initial body weights, the mice treated with the combination showed no significant body weight loss on day 26.

Note

The technical data provided above is for reference only.

References:

1. Cai TY, Liu XW, Zhu H, et al. Tirapazamine sensitizes hepatocellular carcinoma cells to topoisomerase I inhibitors via cooperative modulation of hypoxia-inducible factor-1α. Molecular Cancer Therapeutics, 2014, 13(3): 630-642.

Quality Control